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Summary
 
The signal pathways that control effector function in human natural killer (NK) cells are little
known. In this study, we have identified the critical role of the mitogen-activated protein ki-
nase (MAPK) pathway in NK lysis of tumor cells, and this pathway may involve the mobiliza-
tion of granule components in NK cells upon interaction with sensitive tumor target cells. Ev-
idence was provided by biological, biochemical, and gene transfection methods. NK cell
binding to tumor cells for 5 min was sufficient to maximally activate MAPK/extracellular sig-
nal–regulatory kinase 2 (ERK2), demonstrated by its tyrosine phosphorylation and by its ability
to function as an efficient kinase for myelin basic protein. MAPK activation was achieved in
NK cells only after contact with NK-sensitive but not NK-resistant target cells. In immunocy-
tochemical studies, cytoplasmic perforin and granzyme B were both maximally redirected to-
wards the tumor contact zone within 5 min of NK cell contact with tumor cells. A specific
MAPK pathway inhibitor, PD098059, could block not only MAPK activation but also redistri-
bution of perforin/granzyme B in NK cells, which occur upon target ligation. PD098059 also
interfered with NK lysis of tumor cells in a 5-h 
 
51
 
Cr-release assay, but had no ability to block
NK cell proliferation. Transient transfection studies with wild-type and dominant-negative
MAPK/ERK2 genes confirmed the importance of MAPK in NK cell lysis. These results docu-
ment a pivotal role of MAPK in NK effector function, possibly by its control of movement of
lytic granules, and clearly define MAPK involvement in a functional pathway unlinked to cell
growth or differentiation.
Key words: natural killer cell • mitogen-activated protein kinase • perforin • granzyme B •
signal transduction
 
C
 
ytotoxicity is a key strategy used by the immune sys-
tem to eliminate abnormal cells, be they virus- or par-
asite-infected or transformed (1–3). NK cells play an im-
portant role in this process by their ability to recognize
MHC class I–negative target cells, which escape recogni-
tion by specific cytotoxic T cells. The mechanisms control-
ling NK cell cytotoxicity are gradually being elucidated but
they remain fragmentary. In addition to direct lysis of target
cells, NK cells also display CD16, which allows for their
participation in antibody-dependent cell cytotoxicity of Ig-
coated tumor cells. Intracellular events linked to FcR trig-
gering in NK cells have been studied more extensively, and
activation of protein tyrosine kinases (PTKs)
 
1
 
 appears to be
the initial event (4–6). Rapid phosphorylation of p56lck,
TCR-
 
z
 
, Zap70, and Syk70 have all been reported. This
initial event triggered by FcR cross-linking also leads to phos-
phatidylinositol (PI)-3 kinase and phospholipase C (PLC)–
 
g
 
1
 
Abbreviations used in this paper:
 
 AMAPK, active MAPK; ERK, extracellu-
lar signal–regulatory kinase; KD, kinase deficient; MAPK, mitogen-acti-
vated protein kinase; MBP, myelin basic protein; MEK, MAPK kinase;
PI, phosphatidylinositol; PLC, phospholipase C; TRITC, tetramethyl
rhodamine isothiocyanate.
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activation that, in turn, sets in motion the inositol-1,4,5-
triphosphate cascade and mobilization of intracellular cal-
cium (7, 8). However, the distal events that lead ultimately
to target lysis are not yet known.
For direct lysis of target cells, several investigators have
contributed to the current concept that this action is the re-
sult of a balance of stimulatory and inhibitory receptors on
NK cells (9). The killer cell–inhibitory receptors and CD94/
NKG2 heterodimers in man and the Ly49 family of recep-
tors in mice negatively control the lytic event (10–13). Upon
ligation with MHC class I molecules on the target cells,
these inhibitory receptors suppress the lytic process through
their association with protein tyrosine phosphatases, PTP-
1C and -1D, which may dephosphorylate critical tyrosine
kinases (14–17). Some information on the stimulatory re-
ceptors and their ligands is currently available (18), but little
is known of the internal signal events except that a calcium
and cAMP–dependent pathway leading to inositol triphos-
phate generation is activated upon NK cell binding to its
sensitive target (19–22). What other signals might follow
are not yet determined.
Thus, previous studies have concentrated on signal events
proximal to CD16 or NK receptors. Our goal in this study
was to identify downstream events in NK cells that lead to
target cell lysis. It is well known that both perforin and
serine proteases such as granzyme B are released from NK
cells upon target cell contact (23, 24). The cooperation of
these two molecules results in lysis and apoptosis of the tar-
get cell (25–27). Perforin polymerization and insertion into
the target membrane are reported to cause osmotic leakage
and to provide target cell entry of granzyme B, which trig-
gers the caspase system to lead to DNA fragmentation (28,
29). Our findings demonstrate that NK lysis of tumor tar-
get cells is critically regulated by functional mitogen-acti-
vated protein kinase (MAPK)/extracellular signal–regulated
kinase (ERK), identified to be MAPK/ERK2. This family
of signal molecules was first identified as a serine/threonine
kinase belonging to the signal cascade downstream of
growth factor receptors, and has been studied largely for its
role in cell growth and differentiation (30–36). We report
here that the control of NK lysis by ERK2 may be at the
level of perforin and granzyme B mobilization, and that
ERK2 is involved in the redistribution of these granule
components to the contact zone between NK cells and tar-
get cells.
 
Materials and Methods
 
Cells.
 
A human NK leukemia cell line, YT (a gift from Dr.
Eckhard Podack, University of Miami, Miami, FL), has been used
by us previously to investigate cytolytic function (37). Its ability
to serve as an NK effector cell against a human B lymphoma cell
line, Raji (American Type Culture Collection, Rockville, MD),
was exploited in this study. Another NK-sensitive cell line, K562,
used for measuring function in fresh NK cells, and two NK-resis-
tant tumor cell lines, Jurkat and HL60, were all obtained from
ATCC. All cells were cultured in RPMI 1640 containing 10%
FCS with 2 mM 
 
l
 
-glutamine, 100 U/ml penicillin, 100 
 
m
 
g/ml
streptomycin, and 5 mM Hepes buffer (GIBCO BRL, Gaithers-
burg, MD), hereafter referred to as “medium.”
 
Isolation of LGL from Peripheral Blood.
 
PBMCs were first ob-
tained by Ficoll-Hypaque density centrifugation of leukocyte
buffy coats obtained from normal volunteers at the Southwest
Florida Blood Bank (Tampa, FL). The mononuclear cells were
washed with PBS twice and allowed to adhere to plastic for 1 h at
37
 
8
 
C in medium. The recovered nonadherent cells were further
depleted of adherent cells by incubation on nylon wool columns
for 30 min at 37
 
8
 
C. The cells passing through the columns were
then placed on a four-step discontinuous gradient with a range of
Percoll from 40 to 47.5%, as described previously (3). The cells
recovered from 42.5–45.0% Percoll were assessed visually for
LGL morphology on Giemsa-stained cytocentrifuged slides to
contain routinely 75–90% LGL, and were used to test for NK
function.
 
Chemical Reagents and Antibodies.
 
The MAPK kinase (MEK)1
inhibitor PD098059 (New England Biolabs Inc., Beverly, MA)
was dissolved in DMSO and stored in aliquots at 
 
2
 
20
 
8
 
C (38, 39).
The stock was diluted to the desired working concentration in
RPMI 1640 immediately before use. mAbs against panMAPK/
ERK, ERK1, ERK2, and ERK3 were purchased from Transduc-
tion Laboratories (Lexington, KY). Rabbit antiactive MAPK
(AMAPK) generated against the phosphorylated TEY epitope of
MAPK was purchased from New England Biolabs Inc. Mono-
clonal antiphosphotyrosine, 4G10, rabbit antilyn, and rabbit anti-
MAPK were purchased from Upstate Biotechnology Inc. (Lake
Placid, NY). mAb against granzyme B (2C5) was generated as de-
scribed previously (40). mAb against perforin was purchased from
Endogen, Inc. (Woburn, MA).
 
Cytotoxicity Assay.
 
A 
 
51
 
Cr-release assay was performed as de-
scribed previously, using Raji tumor cells as targets for YT effec-
tor cells, and K562 tumor cells for fresh LGL (3, 37). Briefly, tar-
get tumor cells were labeled with 200 
 
m
 
Ci of Na [
 
51
 
Cr]chromate
(Amersham Corp., Arlington Heights, IL) in 0.2 ml of medium at
37
 
8
 
C in a 5% CO
 
2
 
 atmosphere for 1 h. The cells were then
washed three times and added to effector cells at 5 
 
3
 
 10
 
3
 
 cells/
well in 96-well round-bottomed microplates, resulting in E/T ra-
tios ranging from 50:1 to 3:1 in a final volume of 0.2 ml in each
well. After 5 h incubation at 37
 
8
 
C, 100 
 
m
 
l of culture supernatants
was harvested and counted in a 
 
g
 
 counter. The percent specific
 
51
 
Cr release was determined as described previously (3, 37) ac-
cording to the equation [(experimental cpm 
 
2
 
 spontaneous
cpm)/total cpm incorporated] 
 
3
 
 100. All determinations were
done in triplicate, and the SEM of all assays was calculated and
was typically 
 
z
 
5% of the mean or less.
In assays using the MEK inhibitor, YT cells or fresh LGL at 2.5 
 
3
 
10
 
6
 
 cells/ml were incubated for 1 h at 37
 
8
 
C with serum-free
RPMI 1640, serial dilutions of PD098059, or an equal amount of
DMSO used to dilute the highest concentration of PD098059, in
a total volume of 5 ml in a 25-cm
 
2
 
 tissue culture flask. The cells
were then washed twice with medium and plated into triplicate
wells of a 96-well microplate at various dilutions before 
 
51
 
Cr-
labeled Raji tumor cells were added.
 
Thymidine Uptake Assays.
 
YT cells treated with RPMI 1640,
PD098059, or DMSO as described above for 1 h at 37
 
8
 
C were
washed twice with medium. The YT cells were then cultured in
triplicate wells in a 96-well flat-bottomed plate (5 
 
3
 
 10
 
4
 
 cells/100
 
m
 
l/well) for 24 h at 37
 
8
 
C and pulsed with [
 
3
 
H]thymidine (1 
 
m
 
Ci/
well; Amersham Corp.) for another 6 h of culture before harvest.
The incorporated radioactivity was measured using an automated
liquid scintillation counter.
 
Fixation of Target Cells.
 
Raji, Jurkat, or HL60 tumor cells 
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were washed with PBS once and incubated with 1% paraformal-
dehyde (methanol-free) in PBS, pH 7.4, on ice for 30 min. The
cells were then washed four times with PBS to remove all
paraformaldehyde.
 
Immunoprecipitation and Western Blotting.
 
YT cells were cul-
tured in serum-free medium for 4 h at 37
 
8
 
C before use in order
to reduce the background phosphorylation. The rested YT cells
(10
 
7
 
/ml) were then treated with either serum-free RPMI 1640,
DMSO, or PD098059 for 1 h at 37
 
8
 
C, washed, and mixed with
an equal number of paraformaldehyde-fixed Raji target cells. The
cells were pelleted rapidly at 1,000 rpm in a microcentrifuge at
4
 
8
 
C followed by incubation for 0–15 min at 37
 
8
 
C. Then the cells
were solubilized by incubation at 4
 
8
 
C for 30 min in 1% NP-40,
10 mM Tris, 140 mM NaCl, 0.1 mM PMSF, 10 mM iodoaceta-
mide, 50 mM Na fluoride, 1 mM EDTA, 0.4 mM Na orthovan-
adate, 10 
 
m
 
g/ml leupeptin, 10 
 
m
 
g/pepstatin, and 10 
 
m
 
g/ml apro-
tinin. Cell lysates were centrifuged at 12,000 
 
g
 
 for 15 min to
remove nuclei and cell debris. For immunoprecipitation, lysates
were precleared of nonspecific binding proteins via incubation
with normal rabbit serum or mouse IgG for 1 h at 4
 
8
 
C, followed
by formalin-fixed 
 
Staphylococcus aureus
 
 (Pansorbin; Calbiochem
Corp., La Jolla, CA) or protein A–Sepharose beads (GIBCO
BRL) for 1 h at 4
 
8
 
C, respectively. Lysates containing 1.0 mg pro-
tein/ml were then incubated with 5–10 
 
m
 
g of the indicated anti-
body for 2 h. Immune complexes were collected with protein
A–Sepharose beads and washed three times with washing buffer
(0.1% NP-40, 10 mM Tris, 140 mM NaCl, 0.1 mM PMSF, 10 mM
iodoacetamide, 50 mM Na fluoride, 1 mM EDTA, 0.4 mM Na
orthovanadate). Samples were then boiled for 5 min in loading
buffer and separated by 10% SDS-PAGE, followed by Western
blot analysis with the desired antibody. The proteins were de-
tected by the enhanced chemiluminescence detection system
(ECL; Amersham Corp.).
 
In Vitro Kinase Assays.
 
Cell lysates prepared as described
above were precleared and immunoprecipitated with 5 
 
m
 
g poly-
clonal anti-panMAPK/ERK (Upstate Biotechnology Inc.). The im-
munoprecipitated proteins were collected using protein A–Sepharose
beads, washed, and incubated in a volume of 40 
 
m
 
l with 10 
 
m
 
Ci
of [
 
g
 
-
 
32
 
P]ATP in 30 mM Tris (pH 8.0), 20 mM MgCl
 
2
 
, 2 mM
MnCl
 
2
 
, and 10 
 
m
 
M ATP for 30 min at 30
 
8
 
C with 5 
 
m
 
g of myelin
basic protein (MBP; Upstate Biotechnology Inc.) as a substrate
for MAPK (34). The reaction was terminated with sample buffer
by quick centrifugation, and the mixture was electrophoresed on
a 15% SDS-polyacrylamide gel rather than the 10% gel used
above, in order to detect the small molecular mass of MBP, 18
kD. After drying the gel, 
 
32
 
P-labeled phosphoproteins were de-
tected by autoradiography.
 
Transient Transfection.
 
The CMV promoter–based expression
vector pLNCAL, encoding wild-type or mutant dominant-nega-
tive human ERK2, was used as described previously (41, 42).
The plasmids contained either a catalytically inactive, kinase-defi-
cient (KD) gene, where the critical lysine at position 52 was sub-
stituted for arginine (K52R), or the ERK2 gene that has the Thr
and Tyr residues within the TEY motif substituted with alanine
and phenylalanine (TAYF) or replaced by glutamic acid (TEYE).
YT cells were transfected using the PerFect Lipids transfection kit
(Invitrogen Corp., San Diego, CA), and transfection efficiency in YT
cells was first optimized using the control plasmid pcDNA3.1/
His/lacZ (GAL) included in the kit. Using 
 
b
 
-galactosidase ex-
pression from the control GAL plasmid in YT cells, it was deter-
mined that 4 
 
m
 
g/ml of plasmid DNA provided 35–40% transfec-
tion with the least toxicity. Using the same conditions, YT cells
were transfected with 4 
 
m
 
g/ml of the plasmid containing each of
the various MAPK constructs. 24 h later, the transfected YT cells
were checked for viability by trypan blue exclusion, washed, and
adjusted to the appropriate concentrations of viable cells before
testing for cytotoxicity against Raji tumor cells in a 5-h 
 
51
 
Cr-release
assay. Viability of the transfected cells via this liposome method was
routinely 
 
.
 
90%. An equal aliquot of YT cells, left untransfected
but incubated and treated in an identical manner, was included as
a control.
 
Immunostaining.
 
YT cells pretreated with 100 
 
m
 
M PD098059
or DMSO for 1 h at 37
 
8
 
C and washed were added to Raji cells at
a 1:1 ratio in a total volume of 100 
 
m
 
l, spun rapidly at 1,000 rpm
for 1 min in a cold microcentrifuge, and incubated for 0–5 min at
37
 
8
 
C. The cells were then centrifuged onto a microscope slide
and fixed at 
 
2
 
20
 
8
 
C with methanol/acetone (3:1) for 20 min (43).
The slides were air-dried and rehydrated for 2 h in several
changes of PBS. Polyclonal rabbit antilyn kinase or monoclonal
anti–human perforin or granzyme B was diluted 1:200 with 0.1%
NP-40 in 1% BSA in PBS and applied to the slide for 1 h at room
temperature. After several washes with PBS for 2 h, the slides
were incubated for 25 min at room temperature with goat anti–
rabbit IgG tetramethyl rhodamine isothiocyanate (TRITC)-labeled
antibody (Sigma Chemical Co., St. Louis, MO) diluted 1:80, or
goat anti–mouse Ig FITC-labeled antibody (Sigma Chemical
Co.) diluted 1:100 in 0.1% NP-40 in PBS containing 1% BSA.
After several washes in PBS, the slides were covered with cover-
slips in mounting media of antifade/4,6-diamino-2-phenylindole
(DAPI). Immunofluorescence was observed with an Orthoplan 2
microscope (Ernst Leitz GmbH, Wetzlar, Germany), and images
were captured by a charged coupled device (CCD) camera with
the Smart Capture program (Vysis Inc., Downers Grove, IL). On
each slide, 100 YT–Raji conjugates were evaluated for perforin
or granzyme B mobilization.
Several controls were performed, i.e., YT cells alone or Raji
tumor cells alone stained with no primary antibody but with
FITC-labeled goat anti–mouse Ig or with TRITC-labeled goat
anti–rabbit IgG, to check for nonspecific binding of the second-
ary antibodies. No nonspecific binding of these antibodies was
detected in YT cells or Raji tumor cells in any experiment per-
formed, and these results were omitted from Figs. 8 and 9 for
clarity.
 
Results
 
Suppression of NK Lysis of Tumor Cells by Inhibition of
MAPK.
 
In our first attempt to examine MAPK involve-
ment in NK effector function, we tested the effect of the
specific MAPK pathway inhibitor PD098059 on lysis of
Raji tumor cells by the NK cell line, YT. PD098059 was
identified initially to inhibit the unphosphorylated form of
MEK1 and a constitutively active mutant of MEK1, and
subsequently to inhibit the activation of MEK by c-Raf or
MEK kinase 1 but not the activation of MAPK kinase 4 by
MEK kinase 1 (38, 39). YT cells were pretreated with a
range of concentrations of PD098059 from 10 to 200 
 
m
 
M
for 1 h at 37
 
8
 
C before incubation with 
 
51
 
Cr-labeled Raji
tumor cells for 5 h at 37
 
8
 
C to test for lysis. Representative
data from one of six experiments are shown in Fig. 1 
 
A
 
. A
dose-dependent inhibition by PD098059 was evident at all the
E/T ratios tested. Marked inhibition was seen with 50 
 
m
 
M of
PD098059, with almost complete inhibition achieved with
200 
 
m
 
M. All cells under each treatment remained 100% vi- 
1756
 
MAPK/ERK2 Control of Natural Killer Cell Lytic Function
 
able by assessment of trypan blue exclusion, indicating that
the inhibitor was not nonspecifically toxic. DMSO, used as
a vehicle for PD098059 solubilization, also had no effect.
Thus, the NK effector function can be interfered with by a
MAPK pathway inhibitor. To confirm that fresh NK cells
require this same pathway for lysis of tumor cells, we also
tested the effect of PD098059 on highly enriched Percoll-
fractionated LGL from normal peripheral blood (Fig. 1 
 
B
 
).
Similar inhibition of lytic function was seen with LGL
treated with the same dose range of PD098059. This result
was reproducible with LGL from two other donors (data
not shown).
 
Inhibition of MAPK Does Not Interfere with NK Cell Prolif-
eration.
 
YT cells form a continuous cell line that can be
maintained in culture. Therefore, we next examined
whether MAPK might also control the proliferative cell cy-
cle in YT cells. YT cells were treated with a range of con-
centrations of PD098059 for 1 h at 37
 
8
 
C and then cultured
in medium for 24 h, with [
 
3
 
H]thymidine added for another
6 h. In a representative experiment of four (Fig. 2), it can
be seen that none of the PD098059 concentrations inter-
fered with normal growth of YT cells. Even 200 
 
mM of the
inhibitor did not have a noticeable effect on YT cell prolif-
eration; neither did DMSO. Thus, the results from the first
two sets of experiments suggest that the MAPK pathway
controls the effector function rather than the proliferative
response in YT cells.
Induction of Tyrosine Phosphorylation in MAPK within the
NK Cells by Interaction with Target Cells. The ability of a
highly specific MAPK pathway inhibitor to block NK
function suggests that MAPK must be activated and func-
tional in NK cells during target lysis. Thus, we asked
whether MAPK was constitutively active in NK cells or re-
quired target cell ligation to activate MAPK. We ap-
proached this by biochemical means to determine that
MAPK was activated in NK cells through E/T interaction.
It is well-established that MAPK upon activation becomes
tyrosine phosphorylated (30). Thus, immunoprecipitation
of PTK substrates from YT cell lysates with monoclonal
antiphosphotyrosine antibody, 4G10, and Western blotting
of the immunoprecipitate with the same antibody can first
define whether a tyrosine-phosphorylated band of the pre-
dicted molecular weight of one of the MAPK is detected
upon interaction with tumor cells (Fig. 3 A). To follow this
format, YT cells were added to paraformaldehyde-fixed
Raji tumor cells and lysed immediately (0 min; Fig. 3, lane
3), or the mixture was incubated at 378C for 2–15 min
(lanes 4–6) before lysis. In another group (lane 7), YT cells
were pretreated with 100 mM PD098059 for 1 h at 378C
before incubating with Raji cells for 5 min at 378C. Using
a 10% SDS-polyacrylamide gel for electrophoresis, a ty-
rosine-phosphorylated band at z42/44 kD that correlated
to the p42/44 MAPK was detected as early as 2 min after
Figure 1. Inhibition of NK
lysis by PD098059. (A) YT cells
untreated or treated 1 h at 378C
with 10–200 mM of the MEK1
inhibitor PD098059 or an
amount of DMSO used to dilute
the highest concentration of
PD098059 were tested in tripli-
cate wells for lysis of 51Cr-labeled
Raji tumor cells at the E/T ratios
indicated. (B) Highly enriched
human LGL, freshly isolated by
Percoll gradient centrifugation of
nonadherent PBMCs, were pre-
incubated with PD098059 at
the indicated concentrations for
l h at 378C before testing for lysis
against 51Cr-labeled K562 tumor
cells. The SEM for each mean
percent cytotoxicity of Raji or
K562 tumor cells was ,5% of
the mean, and was not included.
Figure 2. Effect of PD098059 on YT cell proliferation. YT cells un-
treated or treated with 20–200 mM of PD098059 or an amount of
DMSO used to dilute the highest concentration of PD098059 were cul-
tured in triplicate wells for 24 h at 378C before another 6 h pulsing with
[3H]thymidine. The mean and SEM of triplicate wells are shown.1757 Wei et al.
NK cell interaction with target cells. This band peaked at 5
min and was still detectable at 15 min. Similar results were
obtained in two other experiments (data not shown).
However, in PD098059-treated NK cells, incubation with
target cells for 5 min did not induce this phosphorylated
band. As a control, immunoprecipitation with an isotype-
matched IgG was conducted (Fig. 3, lane 8), and no band
was seen in the immunoprecipitate when probed with an-
tiphosphotyrosine. Lysates of YT alone or Raji alone also
showed no bands that could be detected with antiphospho-
tyrosine (lanes 1 and 2). Subsequent experiments used 1-h
pretreatment of NK cells with 100 mM of PD098059.
To confirm that the detected band at 42/44 kD was
MAPK, another experiment was conducted in which YT
cells, before and after treatment with DMSO or 100 mM of
PD098059 for 5 min at 378C, were incubated with Raji
cells and then lysed. The lysates were immunoprecipitated
with antiphosphotyrosine, 4G10, and probed with anti-
panERK, which detects all three known forms (31–33) of
MAPK/ERK (Fig. 3 B). Significantly, upon 5 min interac-
tion with tumor cells, only one band at 42/44 kD was de-
tected in NK cells (lane 2) compared with 0 min incuba-
tion with target cells (lane 1). PD098059 abrogated the
detection of this MAPK in the NK cells (lane 4), whereas
DMSO had no effect (lane 3). Immunoprecipitation with a
control IgG produced no band (lane 5). These data were
reproducible in two other experiments. Thus, it appears
that YT–Raji interactions provoke a specific MAPK path-
way associated with the p42/44 kD form.
Detection of Active MAPK in NK Cells after Activation with
Target Cells. A signature event that identifies MAPK acti-
vation is the phosphorylation of Thr and Tyr in the TEY
motif of the protein (30). MAPK activation in NK cells by
target cells can thus be confirmed by detection of the active
form of MAPK with a specific anti-AMAPK (a-AMAPK)
antibody directed towards the phosphorylated TEY epitope
of the molecule (30). This approach was next pursued by
probing YT whole cell lysates with anti-AMAPK after the
YT cells, which had been untreated or treated with 100 mM
Figure 3. Detection of tyrosine-phosphorylated
p42/p44 MAPK protein in Raji-activated YT ef-
fector cells. (A) YT cells were cultured alone or
with Raji cells at a 1:1 ratio for 0–15 min at 378C.
YT cells were also pretreated with 100 mM of
PD098059 for 1 h at 378C before incubation for 5
min at 378C with Raji tumor cells. The cells were
then lysed and immunoprecipitated (IP) with
monoclonal antiphosphotyrosine, 4G10. Immuno-
precipitation of YT cells, which had been preincu-
bated with Raji tumor cells for 5 min at 378C,
with isotype-matched IgG was also performed as a
control. Raji cells alone were included to check
for background phosphorylation. The immuno-
precipitates were then probed with 4G10 by West-
ern blotting (WB). (B) YT cells were untreated or
pretreated for 1 h at 378C with 100 mM of
PD098059 or an equivalent amount of DMSO used to dilute PD098059. The cells were then mixed with Raji tumor target cells for 0–5 min at 378C
and lysed. The lysates were immunoprecipitated with antiphosphotyrosine, 4G10, or control isotype-matched IgG and then probed with anti-panERK.
Figure 4. Detection of the activated form of MAPK in Raji-triggered
YT effector cells. (A) YT cells untreated or treated with 100 mM of
PD098059 for 1 h at 378C were mixed with equal numbers of Raji tumor
cells for 0–15 min at 378C. Whole cell lysates were then prepared and an-
alyzed by Western blotting (WB) with anti-AMAPK (a-AMAPK) that
was generated against the phosphorylated TEY epitope of MAPK (top).
The blots were then stripped and reprobed with anti-panERK to show
equal loading of all the lanes (bottom). (B) YT cells were mixed with equal
numbers of either Jurkat or HL60 tumor cells, both of which are NK-
resistant, or with the NK-sensitive Raji tumor cells, for 0 or 5 min at
378C. Whole cell lysates were prepared and analyzed by Western blotting
with anti-AMAPK (top). The blots were then stripped and reprobed with
anti-panERK (bottom). (C) YT cells were pretreated with medium
(MED), DMSO, or 10–200 mM of PD098059 for 1 h at 378C before ad-
dition of Raji tumor cells for 0 or 5 min at 378C. Cell lysates were then
prepared and probed with anti-AMAPK (top) and consecutively re-
stripped and reprobed with anti-ERK2 (middle) and anti-ERK1 (bottom).1758 MAPK/ERK2 Control of Natural Killer Cell Lytic Function
of PD098059, had interacted with Raji cells for 0–15 min
(Fig. 4 A). Compared with 0 min incubation (lane 1, top),
AMAPK in NK cells was only detected at 5 min incuba-
tion with tumor cells, and it remained high at 15 min (lanes
2 and 3). However, PD098059-pretreated NK cells
showed a marked reduction in active MAPK upon 15 min
activation with tumor cells (lane 4). To ensure that the dif-
ferences seen were not due to unequal loading of the sam-
ples, the filter was stripped and reblotted with anti-panERK
(bottom). Similar levels of p42/44 ERK were detected in all
four lanes, indicating that its active phosphorylated form
was specifically triggered in NK cells only by target liga-
tion. To examine if MAPK activation is specifically trig-
gered in NK cells only by the appropriate target cells, we
also incubated YT cells with two different NK-resistant tu-
mor cells, Jurkat and HL60, and tested the cell lysates for
the presence of active MAPK (Fig. 4 B). Neither Jurkat nor
HL60 tumor cells can be lysed by YT cells (data not
shown). YT cells preincubated with either Jurkat or HL60
tumor cells at 378C for 5 min showed no active MAPK,
whereas YT cells could be triggered by Raji tumor cells in
the same experiment to produce active MAPK (top). Strip-
ping and reblotting with panERK ensured that the MAPK
proteins were expressed equally before and after 5 min in-
cubation in the three cell mixtures (bottom). Thus, MAPK
activation occurs in NK cells only upon contact with sensi-
tive target cells.
The routine concentration used in this study was 100 mM
of PD098059. To examine if this concentration was suffi-
cient to block MAPK activation completely, YT cells were
pretreated with 10–200 mM of PD098059 for 1 h at 378C
before incubation with Raji tumor cells for 5 min. Cell ly-
sates were then prepared and probed for the presence of ac-
tive MAPK by Western blotting. Fig. 4 C shows a dose-
dependent inhibition, with 10 mM able to block MAPK
activation in YT cells caused by Raji tumor cells, and 50
mM/100 mM able to take the active MAPK level down to
a barely detectable level (top). Stripping and reblotting with
anti-ERK1 and anti-ERK2, respectively, indicated that
both proteins were abundant and equally present in all the
lanes (middle and bottom).
Assessment of Kinase Function of MAPK in Target Cell-acti-
vated NK Cells. To ensure that the MAPK in NK cells af-
ter target ligation was functional, an in vitro kinase assay
was used with MBP as a substrate (34), which is commonly
used for this purpose (Fig. 5, top). YT cells with or without
DMSO or PD098059 pretreatment were incubated with
Raji tumor cells for 0 or 5 min and then lysed for immuno-
precipitation with anti-panERK. The ERK immunopre-
cipitates were tested for their ability to phosphorylate the
MAPK substrate, MBP, and were run on a 15% SDS-poly-
acrylamide gel for easy detection of the small molecular
mass 18-kD MBP substrate. Without incubation, YT cell
lysates showed no ability to phosphorylate MBP (lane 1),
but upon 5 min incubation with target cells, a sharp phos-
phorylated band at the expected molecular weight of MBP
was detected in NK cells treated either with medium or
DMSO (lanes 2 and 3). The phosphorylated MBP band
was not detected in PD098059-treated NK cells even after
5 min incubation with target cells (lane 4). As expected, the
control normal rabbit serum immunoprecipitate from YT
cells, incubated 5 min with target cells, did not show phos-
phorylation of MBP (lane 5). Blotting the same filter with
anti-panERK (bottom), equal amounts of both p42 and p44
forms of ERK were shown to be immunoprecipitated by
anti-panERK in all the lanes. In contrast to the earlier 10%
gels, this experiment using a 15% gel allowed for the detec-
tion of the closely migrating but separate p42 and p44
ERKs. These results suggest that MAPK becomes not only
tyrosine phosphorylated but also functionally activated by
being able to act as a kinase on its substrate, MBP.
Identification of ERK2 as the Active MAPK in Target-ligated
NK Cells. Because ERK1/p44, ERK2/p42, and ERK3/
p97 exist in human cells (31–33), our findings tended to
narrow the responsible ERK to either ERKl or ERK2. To
probe for the specificity of the MAPK that was activated in
NK cells, YT cells with or without DMSO or PD098059
pretreatment were incubated with Raji tumor cells for 0 or
5 min, their lysates were immunoprecipitated with an-
tiphosphotyrosine, and the immunoprecipitates were probed
with anti-ERK2 (Fig. 6 A). ERK2 was readily detectable
among the tyrosine-phosphorylated immunoprecipitates
from DMSO-treated (lane 3) or untreated (lane 2) NK cells
activated 5 min with tumor cells. PD098059 pretreatment
abolished completely the detection of tyrosine-phosphory-
lated ERK2 (lane 4). Probing with antibodies against
ERK1 and ERK3 did not reveal any band (data not
shown).
To further confirm that ERK2 was activated upon target
ligation of NK cells, NK cells similarly treated as above
were lysed and immunoprecipitated with anti-AMAPK,
which specifically recognized the phosphorylated TEY
epitope of MAPK (Fig. 6 B). The immunoprecipitates
were first probed with anti-AMAPK to define accurately
when this form becomes detectable (top). The AMAPK
was only detectable upon 5 min interaction of NK cells
with the tumor cells (lane 2); PD098059 (lane 4) but not
DMSO (lane 3) blocked this detection. Because anti-
AMAPK was a polyclonal rabbit antibody, normal rabbit
Figure 5. Analysis of kinase
function in p42/44 MAPK from
Raji-activated YT effector cells.
YT cells untreated or treated for
1 h at 378C with 100 mM of
PD098059 or an equal concen-
tration of the diluent, DMSO,
were mixed with Raji tumor
cells at a 1:1 ratio for 0–5 min at
378C. The cells were then lysed
and immunoprecipitated (IP)
with anti-panERK. The immunoprecipitates were incubated with [a-
32P]ATP and the 18-kD MBP as a substrate for the in vitro kinase assay in
a 15% SDS gel (top). The filter was then probed with anti-panERK to
show equal loading in all the lanes (bottom). WB, Western blotting. MED,
Medium.1759 Wei et al.
serum was used as a control to immunoprecipitate lysates
from NK cells activated 5 min with target cells. The con-
trol serum did not produce a detectable band (lane 5).
Upon stripping and reprobing with anti-ERK2, the same
band was again detected only in untreated or DMSO-pre-
treated NK cells activated 5 min with tumor cells and not
in the PD098059-treated NK cells (bottom). Probing with
antibodies against ERK1 and ERK3 did not produce any
detectable band (data not shown). The results taken to-
gether demonstrate that MAPK/ERK2 activation was con-
sistently triggered in NK cells upon target ligation.
Downregulation of NK Function by Transient Transfection
with Dominant-Negative MAPK. The activation of MAPK
by NK ligation with target cells and the ability of PD098059
to inhibit NK lysis of the same tumor targets are highly
suggestive of the linkage between MAPK activation and
NK effector function. To further demonstrate this linkage,
we used transient transfection assays (41, 42) to determine
whether expression of dominant-negative p42 MAPK/
ERK2 could inhibit NK lysis of tumor cells. YT cells were
transfected with plasmids encoding either wild-type ERK2
or ERK2 in which the Thr and Tyr residues within the
critical TEY motif that must be phosphorylated for activity
were substituted with glutamic acid (TEYE) or alanine and
phenylanine (TAYF). A plasmid containing the KD form
of ERK2 was also transfected into YT cells. After 24 h of
transfection, YT cells were checked for viability and
washed, and the viable cells were adjusted to the appropri-
ate concentrations for testing in a 5-h 51Cr-release assay
against Raji tumor cells. Comparison was made with an al-
iquot of parental YT cells that had been handled similarly
but without any transfection. Fig. 7 shows a representative
experiment of three with similar results. YT cells trans-
fected with either the KD, TEYE, or TAYF form of
MAPK/ERK2 were markedly deficient in lysis of tumor
cells at all the E/T ratios tested, and all three mutant forms
showed significant inhibition of lysis compared with the
parental nontransfected YT cells at all the E/T ratios tested.
Transfection with wild-type MAPK/ERK2 did not signifi-
cantly alter NK lysis of tumor cells. Therefore, functional
MAPK/ERK2 appears to be required for optimal NK
function against tumor cells.
MAPK Regulation of Perforin Mobilization and Redistribu-
tion in NK Cells. Upon contact with sensitive target cells,
NK cells are known to immediately release perforin and
granzyme B (20, 23, 24). These molecules work in a coor-
dinated manner, with perforin polymerizing into the target
cell membrane at the point of contact and allowing the pas-
sage of lytic enzymes, specifically granzyme B, which can
initiate the apoptotic process in the affected target cells
(25–29). However, little information is available on the in-
tracellular signal mechanisms in NK cells that trigger their
polarization and release. In antibody-dependent cell cyto-
toxicity, FcR triggering in NK cells has been documented
to require PI3 kinase activation, which mediates granule
release (7). Besides PI3 kinase, several molecules, PLC-g,
cAMP, and calcium influx have been associated with gran-
ule exocytosis (7, 8), but further downstream events have
not been explored. Thus, we asked whether MAPK con-
trols perforin mobilization and redistribution in NK cells.
The approach was to examine the pattern of distribution of
cytoplasmic perforin in NK cells before and after conjuga-
Figure 6. Identification of ERK2 as the activated MAPK isoform in
Raji-triggered YT effector cells. (A) YT cells untreated or pretreated 1 h
at 378C with 100 mM of PD098059 or an equivalent amount of the dilu-
ent, DMSO, were mixed with Raji tumor cells at a 1:1 ratio for 0–5 min
at 378C. The cells were then lysed and immunoprecipitated (IP) with an-
tiphosphotyrosine, 4G10, followed by Western blot analysis (WB) with
anti-ERK2. MED, Medium. (B) YT cells similarly treated as in A were
immunoprecipitated with anti-AMAPK (a-AMAPK) and probed with
the same antibody to locate the activated phosphorylated form of MAPK.
The filter was then stripped and reprobed with anti-ERK2 to identify the
activated MAPK isoform as ERK2. NRS, Normal rabbit serum.
Figure 7. Inhibition of NK function by transient transfection with
dominant-negative MAPK/ERK2 in YT effector cells. Equal aliquots of
YT cells were left untransfected or transiently transfected with KD
MAPK/ERK2 in which K52R substitution was constructed, or with mu-
tant ERK2 where Thr and Tyr residues in the TEY motif were replaced
with glutamic acid (TEYE) or with alanine and phenylalanine (TAYF).
The wild-type ERK2 plasmid (WT) was also used to transfect YT cells.
After 24 h at 378C, untransfected and transfected YT cells were assessed
for viability and adjusted to the appropriate concentrations of viable cells
before testing for lysis of 51Cr-labeled Raji tumor cells at the indicated E/T
ratios. The SEM of each mean percent cytotoxicity was ,5%, and was
not shown.1760 MAPK/ERK2 Control of Natural Killer Cell Lytic Function
tion with target cells, and to evaluate the effect of
PD098059. Fig. 8 shows a representative YT–RAJI conju-
gate before and after each treatment. To be able to distin-
guish the effector cells from the tumor cells, it is necessary
to identify a selective marker for each cell type. In screen-
ing several intracellular antigens that exist in Raji cells but
not in YT cells, we determined that the src kinase, lyn, was
a selective marker for Raji cells. YT cells (A) did not stain
with TRITC-labeled antilyn, whereas Raji cells did (D).
On the other hand, only YT cells (C) stained with FITC-
labeled antiperforin; Raji cells did not (B). All cells stained
blue with the nucleus marker. In resting YT cells, perforin
was observed to be evenly distributed throughout the cyto-
plasm in punctated forms (C). DMSO pretreatment of NK
cells did not adversely affect the pattern of FITC-labeled
perforin distribution (E). Upon addition of Raji tumor cells
without any incubation (F), the DMSO-pretreated NK cell
that had bound to TRITC-labeled Raji again showed even
distribution of FITC-labeled perforin in their cytoplasm,
much like the pattern in NK cells without target cells (C
and E). Upon 5 min incubation at 378C with tumor cells
(G), the DMSO-pretreated NK cell that had conjugated
with a target cell showed complete mobilization of intra-
cellular perforin towards the point of contact with the tar-
get cell. Further incubation up to 30 min did not change
this pattern (data not shown), indicating that 5 min of tar-
get cell ligation was sufficient for optimal redistribution of
perforin to the contact point. In contrast, the PD098059-
pretreated NK cell that had formed a conjugate with Raji
tumor cells at 378C for 5 min showed no redistribution of
FITC-labeled perforin, and retained even staining with
FITC-labeled perforin throughout the cytoplasm (H). Enu-
meration of the YT–Raji conjugates indicated that, upon 5
min incubation at 378C, 27% of the conjugates from
DMSO-treated YT cells had mobilized perforin, compared
with 4% of the PD098059-treated YT cell conjugates,
which is similar to the 5% of conjugates that showed mobi-
lization in the control YT–Raji culture at 0 min. Similar
results were obtained in two other experiments (data not
shown). Therefore, functional MAPK appears to be re-
quired to mobilize and redistribute perforin from NK cells
towards the contact point with target cells.
MAPK Regulation of Granzyme B Mobilization and Redis-
tribution in NK Cells. Because granzyme B appears to be
an integral component of the NK lytic process, the next
question was whether MAPK could also control this pro-
cess. Thus, the pattern of distribution of granzyme B in NK
cells before and after target ligation, with or without
PD098059 treatment, was evaluated, and a representative
NK–target conjugate is shown for each group (Fig. 9). The
patterns were identical to those seen with perforin. FITC-
labeled granzyme B was not detected in Raji cells (B) but
was found to be evenly distributed within the cytoplasm of
resting YT cells (C). Raji cells were again labeled with
TRITC-antilyn (D) to distinguish them from YT cells that
are lyn-negative (A). DMSO did not adversely affect the
distribution of granzyme B in NK cells (E). The DMSO-
pretreated NK cell that had bound Raji cells without any
preincubation (F) showed no polarization of granzyme B
towards the target cell. However, upon 5 min incubation
with Raji cells, the DMSO-pretreated NK cell that had
bound a target cell now showed complete redirection of
FITC-labeled granzyme B to the tumor contact site (G). As
with perforin, 5 min was sufficient for complete granzyme
B redirection, and further incubation up to 30 min did not
change the pattern (data not shown). In contrast, the
PD098059-pretreated NK cell did not respond to target
cell ligation by granzyme B polarization (H) and showed an
even distribution of this FITC-labeled enzyme throughout
the cytoplasm. Enumeration of YT–Raji conjugates indi-
cated that upon 5 min incubation at 378C, 28% of the
DMSO-treated YT cell conjugates had mobilized granzyme
B, compared with 3% of the PD098059-treated YT cell
conjugates, which is similar to the 5% of YT–Raji conju-
gates that showed mobilization at 0 min incubation. Two
other experiments produced similar results (data not
shown). Thus, the data depict that MAPK may also regu-
late granzyme B redistribution to the tumor cell site.
Discussion
Our analysis of downstream intracellular signals that oc-
cur in NK cells upon target cell ligation to trigger target ly-
sis has unequivocally identified the MAPK pathway as a
critical component. A specific MAPK, ERK2, is required
for NK effector function, and its primary function may be
to regulate the mobilization and redistribution of cytoplas-
mic perforin and granzyme B towards the contact zone
with target cells. To our knowledge, this is the first direct
evidence of MAPK involvement in a lymphocytic function
that is not associated with gene transcription. MAPK acti-
vation has been investigated in several systems, in both im-
mune-related and nonrelated cells, but the focus has been
on its involvement in either gene induction or cell cycle
control. For example, MAPK has been reported to phos-
phorylate and regulate c-fos, c-myc, myb, Elk-1, Tal-1, Ets-2,
and STAT (signal transducer and activator of transcription)
proteins (42, 44–49). However, it is also becoming evident
that MAPK can act as a kinase for signal molecules that are
not direct transcription factors. For example, activation of
the superoxide generation system that occurs within min-
utes in human neutrophils stimulated with FMLP may in-
volve MAPK-mediated serine/threonine phosphorylation of
several components of the NADPH oxidase, including
p47phox (50). In one report, MAPK/ERK2 was demon-
strated to directly phosphorylate a synthetic peptide of
p47phox (51). Purified cytosolic phospholipase A2 has also
been shown to be directly phosphorylated and activated by
ERK2 (52). It was demonstrated recently that nicotine-
induced secretion from bovine adrenal chromaffin cells also
required MAPK activation (53). In our system, the events
controlled by ERK2 were also extremely rapid: they were
triggered almost immediately, within 5 min, in NK cells
upon target cell binding. From the immunochemistry stud-
ies in this paper, we found that both perforin and granzyme
B were expressed abundantly and were located in a punc-1761 Wei et al.
Figure 8. Inhibition of perforin redistribution in NK cells by PD098059. YT cells pretreated with DMSO or 100 mM of PD098059 for 1 h at 378C
were incubated with an equivalent number of Raji tumor cells for 0–5 min at 378C. The cells were then cytospinned onto microscope slides and stained
with anti–perforin-FITC and/or anti–lyn-TRITC. (A) YT cells stained with anti–lyn-TRITC, (B) Raji tumor cells stained with anti–perforin-FITC,
(C) YT cells stained with anti–perforin-FITC, (D) Raji cells stained with anti–lyn-TRITC, (E) DMSO-pretreated YT cells stained with anti–perforin-
FITC, (F) a DMSO-pretreated YT cell that had bound a Raji tumor cell at 0 min, stained with anti–perforin-FITC/anti–lyn-TRITC, (G) a DMSO-
pretreated YT cell that had bound a Raji tumor cell for 5 min at 378C, stained with anti–perforin-FITC/anti–lyn-TRITC, and (H) a PD098059-pre-
treated YT cell that had bound a Raji tumor cell for 5 min at 378C, stained with anti–perforin-FITC/anti–lyn-TRITC.1762 MAPK/ERK2 Control of Natural Killer Cell Lytic Function1763 Wei et al.
tated distribution throughout the cytoplasm of resting NK
cells. Microscopic analysis of single NK–target conjugates
indicated that interaction with a sensitive tumor target trig-
gered the movement of both perforin and granzyme B to-
wards the point of NK contact with the tumor target, and
in 5 min of interaction, redistribution within the NK cell
cytoplasm of the two lytic molecules was complete such
that only a small area adjacent to the target cell contact
zone contained perforin and granzyme B. Use of a specific
MAPK pathway inhibitor, PD098059 (38, 39), indicated
that pretreatment of NK cells with this reagent could block
completely the redirection of both perforin and granzyme
B towards the target cell in the NK–target conjugate. To
date, studies that have focused on mechanisms of NK lysis
have assessed primarily perforin release and granule exocy-
tosis into the supernatant. The extracellular release of these
lytic components has been shown to require cAMP, PI3
kinase, PLC-g, and calcium mobilization (20–22). Our
work here focused not on extracellular release but on intra-
cellular redirection of perforin and granzyme B. Thus, this
study provides important information on the reorganiza-
tion of the intracellular granules that harbor both perforin
and granzyme B, and suggests that MAPK controls this
process.
The redirection of perforin and granzyme B towards the
contact zone with target cells apparently mediates target ly-
sis. This is confirmed by the ability of the MAPK pathway
inhibitor, PD098059, to also block NK lysis of the tumor
cells in a 5-h 51Cr-release assay. In addition to functional
interference by MAPK inhibition, we also showed by bio-
chemical means that MAPK becomes rapidly tyrosine
phosphorylated and activated in NK cells within 5 min of
interaction with tumor targets. The time frame of maximal
activation of MAPK, i.e., 5 min, coincided with the time
frame of maximal redirection of perforin and granzyme B
to the tumor contact site. Immunoprecipitation with an-
tiphosphotyrosine followed by Western blotting with anti-
panMAPK as well as with anti-ERK–specific antibodies
indicated that only ERK2 and not ERK1 or ERK3 was ac-
tivated by NK to target ligation. The active form of ERK2
could also be documented using a specific antibody di-
rected against the phosphorylated TEY epitope of MAPK.
Additional evidence of functional activation of ERK2 was
provided by the ability of the MAPK isolated from NK
cells that have interacted 5 min with tumor target cells, but
not from NK cells mixed with target cells without prior in-
cubation, to act efficiently as a kinase to phosphorylate
MBP. In all of these experiments, PD098059 pretreatment
of NK cells abolished the phosphorylation and activation of
MAPK. The linkage between MAPK/ERK2 and NK
function was also demonstrated via transient transfection
studies with dominant-negative MAPK/ERK2. YT cells
transiently transfected with either the KD, TEYE, or
TAYF form of ERK2 displayed marked reduction in their
ability to lyse tumor target cells in a 5-h 51Cr-release assay,
whereas wild-type ERK2 transfection had no negative ef-
fect. Finally, specificity of MAPK activation was demon-
strated by the ability of only NK-sensitive Raji but not
NK-resistant Jurkat or HL60 tumor target cells to trigger
phosphorylation of MAPK in YT cells. As an important
correlate, we also demonstrated that MAPK activation was
necessary for fresh NK cell lysis of tumor target cells, by the
ability of PD098059 to block LGL lysis of K562 tumor
cells.
Taken together, the results identify a key downstream
signal molecule, ERK2, that controls NK effector function.
The control appears to be at the level of mobilization of
lytic components, perforin and granzyme B, upon target
cell contact. Thus, our findings add yet another function to
MAPK, and identify lytic regulation by MAPK as a key
point of control in NK cells in our system.
Figure 9. Inhibition of granzyme B redistribution in NK cells by PD098059. YT cells pretreated with DMSO or 100 mM of PD098059 for 1 h at
378C were incubated with an equivalent number of Raji tumor cells for 0–5 min at 378C. The cells were then cytospinned onto microscope slides and
stained with anti–granzyme B-FITC and/or anti–lyn-TRITC. (A) YT cells stained with anti–lyn-TRITC, (B) Raji tumor cells stained with anti–
granzyme B-FITC, (C) YT cells stained with anti–granzyme B-FITC, (D) Raji cells stained with anti–lyn-TRITC, (E) DMSO-pretreated YT cells
stained with anti–granzyme B-FITC, (F) a DMSO-pretreated YT cell that had bound a Raji tumor cell for 0 min, stained with anti–granzyme B-FITC/
anti–lyn-TRITC, (G) a DMSO-pretreated YT cell that had bound a Raji tumor cell for 5 min at 378C, stained with anti–granzyme B-FITC/anti–lyn-
TRITC, and (H) a PD098059-pretreated YT cell that had bound a Raji tumor cell for 5 min at 378C, stained with anti–granzyme B-FITC/anti–lyn-
TRITC.
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